Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1K23HL148527-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will enroll 150 patients with biopsy proven pulmonary sarcoidosis for at least one year who are on any oral treatment regimen for at least six months into a 12-month longitudinal study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in King's Sarcoidosis Health Questionnaire (KSQ) score | The KSQ is a 29-item validated measure of sarcoidosis health status. Scores range from 0 to 100. Higher KSQ scores are better. Lower KSQ scores are worse. | Baseline, 6 months and 12 months |
| Change in St. George's Respiratory Questionnaire (SGRQ) score | The SGRQ is an instrument that contains 50 items in three subscales (symptoms, activity, and impact). Scores range from 100 to 0. Lower scores for the SGRQ are better and higher scores are worse. | Baseline, 6 months and 12 months |
| Change in Forced Expiratory Volume (FEV1) as assessed by Pulmonary Function Testing | Forced Expiratory Volume (FEV1) will be collected by performing Pulmonary Function Testing using spirometry. FEV1 is the maximum amount of air that can be forcibly exhaled in one second. | Baseline, 6 months and 12 months |
| Change in Forced Vital Capacity (FVC) as assessed by Pulmonary Function Testing | Forced Vital Capacity (FVC) will be collected by performing Pulmonary Function Testing using spirometry. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. | Baseline, 6 months and 12 months |
| Change in Diffusing Capacity of Lung for Carbon Monoxide (DLCO) as assessed by Pulmonary Function Testing | Diffusing Capacity of Lung for Carbon Monoxide (DLCO) is a measure of the efficiency of lung gas transfer. DLCO will be collected by performing Pulmonary Function Testing after performing spirometry. | Baseline, 6 months and 12 months |
| Change in 6-minute walk distance |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population will consist of individuals with Sarcoidosis who are seen at the Johns Hopkins Sarcoidosis clinic.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michelle Sharp, MD, MHS | Johns Hopkins University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins Bayview Asthma and Allergy Center | Baltimore | Maryland | 21224 | United States | ||
| Johns Hopkins Greenspring Station |
Not provided
| ID | Term |
|---|---|
| D055118 | Medication Adherence |
| D012507 | Sarcoidosis |
| ID | Term |
|---|---|
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Collecting blood: Complete Blood Count (CBC) with differential. Will also be collecting Peripheral Blood Mononuclear Cells (PBMCs) and some genetic material will be obtained through these PBMCs.
The distance (in meters) a participant is able to walk in 6 minutes will be assessed. |
| Baseline, 6 months and 12 months |
| Change in Modified Medical Research Council Dyspnea Scale (MRC) score | MRC is a simple scale that has been validated as a method of categorizing patients in terms of their disability attributable to dyspnea. The scale has 5 items on it. Scores range from 0 to 4. Higher scores are worse and lower scores are better. | Baseline, 6 months and 12 months |
| Change in Health Care Utilization (HCU) as assessed by the CRISP Database | Health Care Utilization (HCU) for 12 months prior to enrollment and the duration of the study for a total of 24 months will be obtained through the Chesapeake Regional Information System for our Patients (CRISP) database. With consent, researchers are able to receive real-time notifications whenever a participant receives care at any of the hospitals or long-term care facilities. Data available on participants includes records from hospitalizations such as discharge summaries, diagnosis, imaging, and laboratory values. Hospitalization and emergency department (ED) utilization will be coded as a yes/no event. We will also collect self-report hospitalizations and ED visits from the participants at each study visit. | 12 months prior to enrollment and the duration of the study for a total of 24 months |
| Timonium |
| Maryland |
| 21093 |
| United States |
| D001519 | Behavior |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006968 | Hypersensitivity, Delayed |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |